Geographic Atrophy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Geographic Atrophy – Drugs In Development, 2024 report and make more profitable business decisions.
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD), a progressive eye condition affecting the macula, the central part of the retina responsible for detailed central vision. GA specifically refers to a severe and advanced stage of dry AMD. GA is characterized by the gradual degeneration and death of cells in the macula, leading to the formation of sharply defined, well-demarcated areas of atrophy or cell loss. These areas appear as “geographic” patches of damaged retina, giving the condition its name. GA primarily affects central vision, impairing the ability to see fine details, read, drive, or recognize faces. The peripheral vision is typically preserved until later stages of the disease. Symptoms may include blurry or distorted central vision, decreased contrast sensitivity, and difficulty adapting to changes in lighting conditions. Diagnosis of geographic atrophy is typically based on a comprehensive eye examination, including retinal imaging such as optical coherence tomography (OCT) and fundus autofluorescence (FAF) imaging. Risk factors include advanced age, family history of AMD, smoking, and certain genetic factors.
The Geographic Atrophy drugs in development market research report provide comprehensive information on the therapeutics under development for Geographic Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Geographic Atrophy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Geographic Atrophy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 62 molecules, with 60 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Geographic Atrophy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Geographic Atrophy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Geographic Atrophy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4D Molecular Therapeutics IncAdverum Biotechnologies Inc
Akari Therapeutics Plc
Aldeyra Therapeutics Inc
Alexion Pharmaceuticals Inc
Alkeus Pharmaceuticals Inc
Alzheon Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Astellas Pharma Inc
Aviceda Therapeutics Inc
Belite Bio Inc
Boehringer Ingelheim International GmbH
CalciMedica Inc
CIRC Biosciences Inc
Cognition Therapeutics Inc
Complement Therapeutics Ltd
Curative Biotechnology Inc
Disc Medicine Inc
Endogena Therapeutics Inc
Eye Co Pty Ltd
Eyevensys SAS
F. Hoffmann-La Roche Ltd
GenSight Biologics SA
Gyroscope Therapeutics Holdings Ltd
Ikarovec Ltd
Inflammasome Therapeutics Inc
IVERIC bio Inc
Johnson & Johnson
Kriya Therapeutics Inc
Laboratoires Thea SA
Lan-yi Therapeutics Ltd
National Eye Institute
Neuroptika Inc
Novartis AG
NovelMed Therapeutics Inc
Oculis Holding AG
Oculogenex Inc
OliX Pharmaceuticals Inc
ONL Therapeutics Inc
Opsis Therapeutics LLC
Perfuse Therapeutics Inc
Rallybio Corp
Ray Therapeutics Inc
Retrotope Inc
Stealth BioTherapeutics Inc.
Stuart Therapeutics Inc
U.S. National Institutes of Health
Visgenx Inc
Visus Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Geographic Atrophy reports